Document 0742
 DOCN  M95A0742
 TI    FIV vaccine studies. I. Immune response to recombinant FIV env gene
       products and outcome after challenge infection.
 DT    9510
 AU    Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F;
       Bendinelli M; Reubel G; Aubert A; Davis D; Cox D; et al; Department of
       Internal Veterinary Medicine, University of Zurich,; Switzerland.
 SO    Vet Immunol Immunopathol. 1995 May;46(1-2):103-13. Unique Identifier :
       AIDSLINE MED/95343519
 AB    We have vaccinated five groups of cats (n = 25) four times with five
       preparations of recombinant feline immunodeficiency virus (FIV) env gene
       products; one group (n = 7) served as control. The vaccine formulations
       were as follows: (1) envelope glycoprotein of FIV Zurich 2 (FIV Z2)
       expressed in a Baculovirus system and isolated by gel electroelution
       (denatured form); (2) insect cells expressing FIV Z2 glycoprotein; (3)
       envelope glycoprotein of a Boston strain (FIV Bangston) expressed in
       insect cells and isolated by gel electroelution (denatured form); (4)
       glycosylated Bangston envelope protein made in insect cells and isolated
       in a native form; (5) non-glycosylated Bangston envelope protein made in
       Escherichia coli. All cats were challenged with 20 50% cat infective
       doses (CID50) of FIV Z2 previously titrated in cats. All vaccinated cats
       developed high enzyme-linked immunosorbent assay (ELISA) antibodies to
       the homologous antigen; crossreactivity to heterologous antigens was
       seen at a lower level. Virus neutralizing antibodies (tested with
       Petaluma virus) reached titers up to 32. After challenge, all cats
       seroconverted (as judged by anti gag antibodies in Western blot) and
       became infected (as judged by virus isolation and/or polymerase chain
       reaction) between 4 and 11 weeks with the exception of one cat. It is
       concluded that it is relatively easy to induce high ELISA antibody
       titers using recombinant env gene products, ELISA antibody titers do not
       correlate with virus neutralization or with protection.
 DE    Animal  Antibodies, Viral/*BIOSYNTHESIS  Antigens, Viral/IMMUNOLOGY
       Blotting, Western/VETERINARY  Cats  Enzyme-Linked Immunosorbent
       Assay/VETERINARY  Feline Acquired Immunodeficiency
       Syndrome/IMMUNOLOGY/*PREVENTION  & CONTROL  Female  Gene Products,
       env/GENETICS/*IMMUNOLOGY  Genes, env  Immunodeficiency Virus,
       Feline/GENETICS/*IMMUNOLOGY/ISOLATION &  PURIF  Leukocytes,
       Mononuclear/VIROLOGY  Male  Neutralization Tests/VETERINARY  Polymerase
       Chain Reaction/VETERINARY  Specific Pathogen-Free Organisms  Support,
       Non-U.S. Gov't  Vaccination/VETERINARY  Vaccines, Synthetic/IMMUNOLOGY
       Viral Vaccines/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).